Amgen (AMGN) Stock Price vs Net Income
Open the interactive overlay on autario.com.
Between Q3 2020 and Q3 2021, Amgen's net income declined 23.7%, falling from $7.35 billion to $5.61 billion. Over the same period, the stock price decreased 16.3%, from $254.16 to $212.65. Because net income fell more steeply than the stock price, Amgen's valuation expanded relative to its earnings during this window. As of June 2, 2026, the stock traded at $326.42, representing a 53.4% increase from the Q3 2021 price, while the most recent reported net income remains from September 30, 2021 at $5.61 billion.
Trailing-12-month Net Income was $5.6B as of 2021-09-30, -24% year over year. The stock moved -16% over the same window ($254.16 -> $212.65). Price and Net Income moved almost in lockstep.
Latest close: 326.62 USD (2026-06-02).
Net Income | recent SEC reports
| Report date | Net Income | Period |
|---|
| 2021-09-30 | 5.6B USD | Q3 10-Q |
| 2021-06-30 | 5.7B USD | Q3 10-Q |
| 2021-03-31 | 7.1B USD | Q3 10-Q |
| 2020-12-31 | 7.3B USD | FY 10-K |
| 2020-09-30 | 7.4B USD | Q3 10-Q |
| 2020-06-30 | 7.3B USD | Q3 10-Q |
| 2020-03-31 | 7.7B USD | Q3 10-Q |
| 2019-12-31 | 7.8B USD | FY 10-K |
Sources: autario.com/data/stock-amgn-amgen-daily-prices · autario.com/data/amgen-net-income-sec-filings | data verified and hosted on autario.com.